GlassScriptPhysician profile
Tracey L Evans
NPI 1033152319
$499,960.32
in general payments reported to CMS, 2019-2025
63 companies · $55K in 2025
The $55K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $94K · 2021: $67K · 2022: $57K · 2023: $55K · 2024: $31K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Consulting Fee: $14K · Food and Beverage: $8,861 · Honoraria: $8,588 · Travel and Lodging: $5,128 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,648.50 |
| Consulting Fee | $14,325.00 |
| Food and Beverage | $8,860.53 |
| Honoraria | $8,588.00 |
| Travel and Lodging | $5,128.30 |
| Education | $117.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291,868.42 | 2019-2025 | Tagrisso, Imfinzi, Datroway |
| Jazz Pharmaceuticals INC. | $86,199.74 | 2019-2025 | |
| Genentech USA, INC. | $46,857.90 | 2019-2024 | Venclexta, Polivy, Perjeta |
| Mirati Therapeutics, INC. | $29,906.00 | 2023-2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $18,751.43 | 2019-2024 | Opdivo, Eliquis, Opdualag |
| Merck Sharp & Dohme LLC | $10,755.64 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novocure INC. | $5,416.61 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $2,122.64 | 2021-2025 | Libtayo |
| Seagen INC. | $648.12 | 2019-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $596.41 | 2019-2025 | |
| Pfizer INC. | $580.04 | 2019-2024 | |
| Celgene Corporation | $508.13 | 2019-2024 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $397.36 | 2019-2025 | Injectafer, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $347.59 | 2019-2024 | Fruzaqla, Alunbrig, Ninlaro |
| Eisai INC. | $340.41 | 2019-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $288.00 | 2019-2024 | Xospata, Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $283.63 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $279.79 | 2020-2024 | |
| Abbvie INC. | $278.73 | 2021-2024 | |
| Incyte Corporation | $277.07 | 2019-2024 | Monjuvi, Pemazyre, Jakafi |
| Amgen INC. | $274.84 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Lilly USA, LLC | $228.28 | 2019-2023 | Retevmo, Jaypirca, Verzenio |
| Janssen Biotech, INC. | $191.96 | 2019-2024 | Erleada, Akeega, Balversa |
| Tempus Ai, INC | $186.66 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $157.67 | 2021-2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $152.73 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $133.87 | 2019-2025 | |
| Gilead Sciences, INC. | $127.45 | 2022-2024 | |
| Sobi, INC | $124.49 | 2022-2024 | |
| Blueprint Medicines Corporation | $121.62 | 2020-2024 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $121.34 | 2021-2025 | Monoferric |
| Stemline Therapeutics INC. | $89.86 | 2019-2020 | |
| Taiho Oncology, INC. | $80.21 | 2019-2022 | |
| G1 Therapeutics, INC. | $79.38 | 2022-2023 | Cosela |
| Array Biopharma INC | $78.83 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Genentech, INC. | $76.27 | 2025 | Tecentriq |
| Octapharma USA, INC. | $76.10 | 2019-2023 | Panzyga |
| Foundation Medicine, INC. | $75.62 | 2019-2023 | |
| Glaxosmithkline, LLC. | $75.46 | 2022-2025 | Ojjaara |
| Puma Biotechnology, INC. | $73.94 | 2021 | |
| Kite Pharma, INC. | $65.60 | 2022-2024 | Yescarta |
| Beigene USA, INC. | $64.85 | 2021-2023 | Brukinsa |
| Janssen Pharmaceuticals, INC | $56.06 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.56 | 2020-2022 | |
| Exelixis INC. | $50.99 | 2019-2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $41.85 | 2023 | Myrisk |
| Teva Pharmaceuticals USA, INC. | $41.14 | 2019-2020 | |
| Tolmar, INC. | $39.32 | 2023-2024 | |
| Myovant Sciences INC. | $35.99 | 2022 | |
| Rigel Pharmaceuticals, INC. | $34.70 | 2022-2024 | Tavalisse, Rezlidhia |
| Progenics Pharmaceuticals, INC. | $29.19 | 2024 | |
| Telix Pharmaceuticals | $26.05 | 2023 | Illuccix |
| Caris Mpi, INC. | $22.63 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $22.55 | 2023 | Besremi |
| Dova Pharmaceuticals | $22.15 | 2021 | |
| Sumitomo Pharma America, INC. | $19.64 | 2024 | Orgovyx |
| Amneal Pharmaceuticals LLC | $19.45 | 2023 | Avastin |
| Dendreon Pharmaceuticals LLC | $17.53 | 2022 | |
| Eusa Pharma (US) LLC | $16.67 | 2021 | |
| Coherus Oncology, INC. | $16.15 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.09 | 2019 | |
| Tersera Therapeutics LLC | $14.82 | 2019 | |
| Clovis Oncology, INC. | $5.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.